Aigen Investment Management LP Invests $286,000 in Natera, Inc. (NASDAQ:NTRA)

Aigen Investment Management LP purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,805 shares of the medical research company’s stock, valued at approximately $286,000.

Several other institutional investors have also modified their holdings of NTRA. QRG Capital Management Inc. purchased a new stake in shares of Natera during the 3rd quarter worth approximately $671,000. Principal Financial Group Inc. lifted its stake in Natera by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,012,498 shares of the medical research company’s stock valued at $128,537,000 after buying an additional 28,751 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in Natera in the 3rd quarter valued at approximately $126,000. Assetmark Inc. lifted its stake in Natera by 2.1% in the 3rd quarter. Assetmark Inc. now owns 7,353 shares of the medical research company’s stock valued at $933,000 after buying an additional 150 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on NTRA. TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Finally, Barclays initiated coverage on Natera in a research note on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.56.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 4,858 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total value of $809,294.22. Following the completion of the sale, the insider now owns 114,912 shares in the company, valued at approximately $19,143,190.08. This trade represents a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 87,272 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 301,571 shares of company stock valued at $48,322,810 over the last three months. 7.60% of the stock is owned by company insiders.

Natera Trading Down 0.6 %

NASDAQ NTRA opened at $140.66 on Friday. The firm has a market capitalization of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The company’s 50 day moving average price is $165.61 and its 200 day moving average price is $147.70.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.